Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin plus pembrolizumab versus chemoradiotherapy for muscle-invasive bladder cancer with bladder preservation
2026-525612-34-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of enfortumab vedotin and pembrolizumab in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Pfizer. Primary endpoints: Bladder-intact event-free survival and Overall survival. Planned start Oct 2026; status: authorised.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2026-525612-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525612-34-00.